Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis

被引：8

作者：

Ohashi, Kadoaki ^{[1
]}

Ninomiya, Kiichiro ^{[1
]}

Yoshioka, Hiroshige ^{[2
,20
]}

Bessho, Akihiro ^{[3
]}

Shibayama, Takuo ^{[4
]}

Aoe, Keisuke ^{[5
]}

Ishikawa, Nobuhisa ^{[6
]}

Kozuki, Toshiyuki ^{[7
]}

Kawai, Haruyuki ^{[8
]}

Kuyama, Shoichi ^{[9
]}

Miyoshi, Seigo ^{[10
]}

Fujitaka, Kazunori ^{[11
]}

Obata, Hideto ^{[12
]}

Tsubata, Yukari ^{[13
]}

Awaya, Yoshikazu ^{[14
]}

Inoue, Masaaki ^{[15
]}

Inoue, Koji ^{[16
]}

Horita, Naokatsu ^{[17
]}

Yanai, Hiroyuki ^{[18
]}

Hotta, Katsuyuki ^{[19
]}

Kiura, Katsuyuki ^{[1
]}

机构：

[1] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan

[2] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan

[3] Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Japan

[4] Natl Hosp Org, Dept Resp Med, Okayama Med Ctr, Okayama, Japan

[5] Natl Hosp Org, Dept Med Oncol, Yamaguchi Ube Med Ctr, Ube, Yamaguchi, Japan

[6] Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Japan

[7] Natl Hosp Org, Shikoku Canc Ctr, Dept Thorac Oncol & Med, Shikoku, Ehime, Japan

[8] Okayama Saiseikai Gen Hosp, Dept Internal Med, Okayama, Japan

[9] Iwakuni Med Ctr, Dept Resp Med, Iwakuni, Japan

[10] Ehime Univ, Grad Sch Med, Dept Cardiol Pulmonol Hypertens & Nephrol, Matsuyama, Ehime, Japan

[11] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan

[12] Yamaguchi Ken Saiseikai Shimonoseki Gen Hosp, Dept Resp Med, Shimonoseki, Yamaguchi, Japan

[13] Shimane Univ, Fac Med, Div Med Oncol & Resp Med, Dept Internal Med, Matsue, Shimane, Japan

[14] Miyoshi Cent Hosp, Dept Resp Med, Saitama, Japan

[15] Shimonoseki City Hosp, Dept Chest Surg, Shimonoseki, Yamaguchi, Japan

[16] Ehime Prefectural Cent Hosp, Dept Resp Med, Matsuyama, Ehime, Japan

[17] Kure Kyosai Hosp, Dept Resp Med, Kure, Hiroshima, Japan

[18] Okayama Univ Hosp, Dept Pathol, Okayama, Japan

[19] Okayama Univ Hosp, Ctr Innovat Clin Med, 2-5-1 Shikata Cho Kita Ward, Okayama 7008558, Japan

[20] Kansai Med Univ Hosp, Dept Thorac Oncol, Hirakata, Osaka, Japan

来源：

LUNG CANCER | 2020年 / 150卷

关键词：

Epidermal growth factor receptor mutations; Performance status; Human epidermal growth factor receptor-2; Time-To-Treatment failure; GROWTH-FACTOR RECEPTOR; ACQUIRED-RESISTANCE; TRASTUZUMAB EMTANSINE; GENE-MUTATIONS; PHASE-II; CANCER; MUTANT; AMPLIFICATION; OVEREXPRESSION; ADENOCARCINOMA;

D O I：

10.1016/j.lungcan.2020.09.024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatment for EGFR-mutated non-small-cell lung carcinoma (NSCLC); however, a biomarker to predict their efficacy has not been established. Although human epidermal growth factor receptor-2 (HER2) aberrations constitute a potential mechanism for acquired resistance to EGFR-TKIs, the impact of HER2 on EGFR-TKI treatment outcomes has not been systematically evaluated. In this post-hoc subgroup study, we examined the impact of HER2 on the effect of EGFR-TKIs in patients with NSCLC harboring EGFR mutations. Materials and Methods: Of 1126 patients with NSCLC enrolled into a prospective cohort study (HER2-CS study), we analyzed data of 356 (32 %) patients with EGFR-mutant tumors. HER2 protein expression levels were determined by immunohistochemistry (IHC) with the gastric cancer criteria. Patients were divided either to an HER2-P group (HER2-IHC2+/3+) or an HER2-N group (HER2-IHC0/1+). We primarily assessed differences in the time-to-treatment failure (TTF) of EGFR-TKI between the groups. Results: The HER2 scoring was as follows: IHC0 (n = 76, 21 %), IHC1+ (n = 199, 56 %), IHC2+ (n = 72, 20 %), and IHC3+ (n = 9, 3 %). The patients' demographics were similar in the HER2-P and HER2-N groups. The HER2-P group showed a significantly shorter EGFR-TKI TTF than the HER2-N group (hazard ratio [HR]: 1.657, 95 % confidence interval [CI]: 1.076-2.552; median: 13.3 vs. 19.1 months). The magnitude of the negative impact of TTF was especially dependent on performance status (PS). HER2 expression significantly deteriorated the TTF in the subgroup with PS 2 (HR: 5.497, 95 % CI: 1.510-20.02), but not in that with better PS (HR: 1.437, 95 % CI: 0.899-2.298) (pinteraction = 0.015). Conclusion: In the current cohort, HER2 protein expression in EGFR-mutant NSCLC may have a negative impact on the effect of EGFR-TKIs, the effect of which was PS dependent.

引用

页码：83 / 89

页数：7

共 50 条

[21] EGFR and HER2 expression in advanced biliary tract cancer
Harder, Jan
Waiz, Oliver
Otto, Florian
Geissler, Michael
Olschewski, Manfred
Weinhold, Brigitte
Blum, Hubert E.
Schmitt-Graeff, Annette
Opitz, Oliver G.
WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (36) : 4511 - 4517
[22] Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas
Tang, Daoqiang
Liu, Charles Y. J.
Shen, Danping
Fan, Shuqiong
Su, Xinying
Ye, Peng
Gavine, Paul R.
Yin, Xiaolu
ONCOTARGETS AND THERAPY, 2015, 8 : 7 - 14
[23] Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Foster, Scott A.
Whalen, Daniel M.
Oezen, Aysxeguel
Wongchenko, Matthew J.
Yin, JianPing
Yen, Ivana
Schaefer, Gabriele
Mayfield, John D.
Chmielecki, Juliann
Stephens, Philip J.
Albacker, Lee A.
Yan, Yibing
Song, Kyung
Hatzivassiliou, Georgia
Eigenbrot, Charles
Yu, Christine
Shaw, Andrey S.
Manning, Gerard
Skelton, Nicholas J.
Hymowitz, Sarah G.
Malek, Shiva
CANCER CELL, 2016, 29 (04) : 477 - 493
[24] Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains
Li, Chenguang
Sun, Yihua
Fang, Rong
Han, Xiangkun
Luo, Xiaoyang
Wang, Rui
Pan, Yunjian
Hu, Haichuan
Zhang, Yang
Pao, William
Shen, Lei
Ji, Hongbin
Chen, Haiquan
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (01) : 85 - 89
[25] The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center
Xiong, Yicheng
Bian, Dongliang
Huang, Zhida
Yu, Huansha
Huang, Jie
Zhang, Peng
He, Wenxin
Liu, Hongcheng
FRONTIERS IN ONCOLOGY, 2023, 13
[26] Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer
Patil, Tejas
Mushtaq, Rao
Marsh, Sydney
Azelby, Christine
Pujara, Miheer
Davies, Kurtis D.
Aisner, Dara L.
Purcell, William T.
Schenk, Erin L.
Pacheco, Jose M.
Bunn, Paul A.
Camidge, D. Ross
Doebele, Robert C.
CLINICAL LUNG CANCER, 2020, 21 (03) : E191 - E204
[27] Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
Baraibar, Iosune
Mezquita, Laura
Gil-Bazo, Ignacio
Planchard, David
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 148
[28] EGFR and HER2 expression in cervical cancer patients in Ibadan, Nigeria
Orekoya, Ajibike Ayomide
Abdus-Salam, Abbas A.
Oyesegun, Abdurasaq R.
Ntekim, Atara, I
Folasire, Ayorinde M.
Okolo, Clement A.
Olabumuyi, Adeniyi A.
Dada, Adedamola A.
Adenipekun, Adeniyi A.
ECANCERMEDICALSCIENCE, 2023, 17
[29] Study of Programmed Death Ligand 1 and EGFR/HER2 Expression in Non-Small-Cell Lung Carcinoma With a Clinicopathological Spectrum
Laishram, Devina
Raphael, Vandana
Marbaniang, Evarisalin
Harris, Caleb
Jagtap, Vikas
Wankhar, Baphiralyne
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (07)
[30] EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort
Varella-Garcia, Marileila
Mitsudomi, Tetsuya
Yatabe, Yashushi
Kosaka, Takayuki
Eiji, Nakajima
Xavier, Ana Carolina
Skokan, Margaret
Zeng, Chan
Franklin, Wilbur A.
Bunn, Paul A., Jr.
Hirsch, Fred R.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (03) : 318 - 325

← 1 2 3 4 5 →